Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Burn-Out Syndrome, Post-Traumatic Stress...
Phase NA
Enrollment 195
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

This study plans to learn if creative arts programs that include visual, musical, written, or physical expression can reduce symptoms of burnout syndrome, Post Traumatic Stress Disorder (PTSD), depression, and anxiety in critical care healthcare professionals. This study also explores if creative arts can enhance the connection to the purpose of work, the development of adequate coping skills, while providing time to connect with peers.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Visual Arts — Subjects meet for 90 minutes, once weekly, over 12 weeks for guided drawing/sketching sessions. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community. Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation.
  • Behavioral: Music — Subjects meet for 90 minutes, once weekly, over 12 weeks, for guided music-listening exercises (such as lyric analysis, patient-chosen, music for relaxation and/or visualization) and active music making. The 12 sessions follow a standard sequence, addressing three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community. Surveys, activity diary cards are completed at baseline, weekly and at completion to assess satisfaction, stress, and well-being. Qualitative focus groups, after the intervention, assess acceptability of intervention, outcomes, program development and implementation.
  • Behavioral: Dance/Movement — Subjects will meet once weekly, and begin with a movement check-in, a gentle physical warm-up, and then either a structured or improvisational movement process. for a total of 12 weeks. Each session will last 90 minutes. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community. Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation.
  • Behavioral: Writing/Poetry — Subjects will meet once weekly, for writing workshops to encourage participants to tell the stories they need to tell, using integral elements of good writing, for a total of 12 weeks. Each session will last 90 minutes. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community. Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation.
  • Behavioral: Control — Control Group will only complete surveys at baseline and 12 weeks later.

Primary Outcomes

  • Acceptability/Satisfaction of Intervention as assessed by Client Satisfaction Questionnaire (CSQ-8) scores to yield a homogeneous estimate of general satisfaction. (At the end of 12 week intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2020-03-01
Completion: 2025-04-30
Eligibility
Age: 18 Years – 85 Years
Sex: ALL
Volunteers: true
Enrollment: 195 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Colorado, Denver
Collaborators: National Endowment for the Arts, United States
Principal Investigators:
  • Marc Moss, MD (PRINCIPAL_INVESTIGATOR) - University of Colorado, Denver
Contact Information
Study Contact:
Rafaela Mantelli, BS
303-724-6377
rafaela.mantelli@cuanschutz.edu
Jeffrey McKeehan, MSN
303-724-6080
jeffrey.mckeehan@cuanschutz.edu
Jeffrey McKeehan, MSN
303-724-6080
jeffrey.mckeehan@ucdenver.edu
University of Colorado - Anschutz Medical Campus
Interventions
  • Behavioral: Visual Arts — Subjects meet for 90 minutes, once weekly, over 12 weeks for guided drawing/sketching sessions. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community. Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation.
  • Behavioral: Music — Subjects meet for 90 minutes, once weekly, over 12 weeks, for guided music-listening exercises (such as lyric analysis, patient-chosen, music for relaxation and/or visualization) and active music making. The 12 sessions follow a standard sequence, addressing three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community. Surveys, activity diary cards are completed at baseline, weekly and at completion to assess satisfaction, stress, and well-being. Qualitative focus groups, after the intervention, assess acceptability of intervention, outcomes, program development and implementation.
  • Behavioral: Dance/Movement — Subjects will meet once weekly, and begin with a movement check-in, a gentle physical warm-up, and then either a structured or improvisational movement process. for a total of 12 weeks. Each session will last 90 minutes. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community. Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation.
  • Behavioral: Writing/Poetry — Subjects will meet once weekly, for writing workshops to encourage participants to tell the stories they need to tell, using integral elements of good writing, for a total of 12 weeks. Each session will last 90 minutes. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community. Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation.
  • Behavioral: Control — Control Group will only complete surveys at baseline and 12 weeks later.
Study Locations (1 sites)
University of Colorado - Anschutz Medical Campus, Aurora, Colorado 80045 United States
Eligibility Criteria
Inclusion Criteria: * Employed as a healthcare provider, practicing primarily in a hospital setting for at least 20 hours per week. * Positive symptoms of burnout measured via the Maslach Burnout Inventory (MBI): * emotional exhaustion score of \>17, or * depersonalization score of \>7, or * personal accomplishment score of \< 31. Exclusion Criteria: • Unwillingness to participate in any of the four creative arts interventions.
Conditions Suicide, Depression
Phase PHASE2
Enrollment 472
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

This study plans to learn more about the use of one of two self-guided online cognitive behavioral therapy courses. One is focused on symptoms of depression and one is focused on history of suicidal thoughts and behaviors.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: c-CBT for Suicide Prevention — Online c-CBT for SP The computerized Cognitive Behavioral Therapy for Suicide Prevention (cCBT-SP) course is comprised of 12 online sessions and is augmented by use of a companion workbook.
  • Behavioral: c-CBT or Depression — The computerized Cognitive Behavioral Therapy for Depression (cCBT-D) course is comprised of 12 online sessions and is augmented by use of a companion workbook.

Primary Outcomes

  • Client Satisfaction Questionnaire (12 weeks)
  • Internet Evaluation and Utility Questionnaire (12 weeks)
  • Internet Impact and Effectiveness Questionnaire (12 weeks)
  • Narrative Evaluation of Intervention Interview (12 weeks)
  • Recruitment Rate (12 weeks)
  • Completion of intervention (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-03-20
Completion: 2026-08-30
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: true
Enrollment: 472 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: VA Eastern Colorado Health Care System
Principal Investigators:
  • Lisa A Brenner, PhD (PRINCIPAL_INVESTIGATOR) - VA Eastern Colorado Health Care System
Contact Information
Study Contact:
Kelly A Stearns-Yoder, MA
720-723-6477
kelly.stearns@va.gov
Lisa A Brenner, PhD
720-723-6488
Lisa.Brenner@va.gov
Eastern Colorado Health Care System
Kelly A Stearns-Yoder, MA
720-723-6477
Kelly.Stearns@va.gov
Eastern Colorado Health Care System
Interventions
  • Behavioral: c-CBT for Suicide Prevention — Online c-CBT for SP The computerized Cognitive Behavioral Therapy for Suicide Prevention (cCBT-SP) course is comprised of 12 online sessions and is augmented by use of a companion workbook.
  • Behavioral: c-CBT or Depression — The computerized Cognitive Behavioral Therapy for Depression (cCBT-D) course is comprised of 12 online sessions and is augmented by use of a companion workbook.
Study Locations (1 sites)
Eastern Colorado Health Care System, Aurora, Colorado 80045 United States
Eligibility Criteria
Cohort A - cCBT-SP Program Inclusion Criteria: 1. Veterans between the ages of 18 and 65 2. Currently living in Colorado, New York, Montana, Texas, or Utah who have accessed VA Care 3. Recent suicidal ideation (past month; C-SSRS Screener -Yes to Item 2) and history of lifetime suicidal behavior (lifetime, C-SSRS Screener - Yes to Item 6) 4. Reliable access to a computer/tablet and the internet 5. Ability to provide informed consent Exclusion Criteria: 1. Active alcohol or substance use disorder, excluding Cannabis dependence, as determined by screening or electronic medical record 2. Identification of active psychosis or bipolar disorder, as determined via screening or electronic medical record 3. Severe cognitive impairment, as determined by screening or electronic medical record 4. Currently enrolled in/participating in another mental health-related intervention research study Cohort B - cCBT-D Program Inclusion Criteria: 1. Veterans between the ages of 18 and 65 2. Currently living in Colorado, New York, Montana, Texas, or Utah who have accessed VA care 3. Mild to moderate depressive symptoms, as determined by the PHQ-9, (score of 5-14) 4. Reliable access to a computer/tablet and the internet 5. Ability to provide informed consent Exclusion Criteria: 1. PHQ-9 score below 4 or 15 and above 2. Active alcohol or substance use disorder, excluding Cannabis dependence, as determined by screening or electronic medical record 3. Identification of active psychosis or bipolar disorder, as determined via screening or electronic medical record 4. Severe cognitive impairment, as determined by screening or electronic medical record 5. Currently enrolled in/participating in other intervention research study
Conditions Depression, Anxiety
Phase NA
Enrollment 68
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this randomized controlled trial is to evaluate the effectiveness of the Safe Haven app in reducing mental health symptoms and enhancing mental health literacy in undergraduates at a national university in southern Taiwan. The main questions it aims to answer are: Does the Safe Haven app lead to significantly greater reductions in general psychological distress, depression, anxiety, and stress compared to standard campus care? Does the app result in greater improvements in mental health literacy among participants? Researchers will compare an experimental group (receiving the Safe Haven app in addition to standard campus care) to a waitlist control group (receiving standard campus care only) to see if the intervention provides superior improvements in mental health outcomes over time. Participants will: Complete online assessments at three time points: baseline (T0), post-intervention (3 months, T1), and follow-up (3 months post-intervention, T2). Experimental Group: Download the Safe Haven app to complete daily mood self-monitoring and weekly assessments, and receive psychoeducational content, personalized suggestions for 3 months. Control Group: Maintain access to standard campus care and receive access to the app after the final follow-up assessment.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Safe Haven App — A Just-in-Time Adaptive Intervention (JITAI) mobile app that integrates self-monitoring, risk stratification, and tailored psychoeducation modules. The system provides real-time feedback and stepped-care support based on the user's psychological status.

Primary Outcomes

  • Depression, Anxiety, and Stress Symptoms (DASS-21) (Baseline, Post-intervention (Month 3), and Follow-up (Month 6))
  • General Psychological Distress (CHQ-12) (Baseline, Post-intervention (Month 3), and Follow-up (Month 6))
  • Mental Health Literacy (MHLS-HPG) (Baseline, Post-intervention (Month 3), and Follow-up (Month 6))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-16
Completion: 2027-01-31
Eligibility
Age: 18 Years – 24 Years
Sex: ALL
Volunteers: true
Enrollment: 68 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Cheng-Kung University Hospital
Principal Investigators:
  • Ching-Lan Lin (PRINCIPAL_INVESTIGATOR) - National Cheng Kung University
Contact Information
Study Contact:
Ching-Lan Lin
+886-6-2757575
chinglan@mail.ncku.edu.tw
Jou-Ting Lin
+886-6-2757575
t28121055@gs.ncku.edu.tw
Ching-Lan Lin, Doctor
+886-6-2757575
chinglan@mail.ncku.edu.tw
National Cheng Kung University
Interventions
  • Behavioral: Safe Haven App — A Just-in-Time Adaptive Intervention (JITAI) mobile app that integrates self-monitoring, risk stratification, and tailored psychoeducation modules. The system provides real-time feedback and stepped-care support based on the user's psychological status.
Study Locations (1 sites)
National Cheng Kung University, Tainan, 70101 Taiwan
Eligibility Criteria
Inclusion Criteria: * registered undergraduates aged 18-24 years * own a personal smart device (mobile phone or tablet) * ability to read Chinese * willingness to install the study app and complete the follow-up assessments. Exclusion Criteria: * are on leave of absence or not officially enrolled during the study period * are participating in another mental health intervention program or using similar mental health apps.

Sleep Health in U.S. Marines

NCT07420205
Recruiting
Conditions Depression, Suicidality, Sleep
Phase PHASE2
Enrollment 860
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to test a sleep health program designed specifically for U.S. Marine Corps personnel. Researchers want to determine if this program helps Marines improve the participants sleep quality and overall mental health. The study will evaluate whether the program improves sleep quality and duration and reduces symptoms of depression, anxiety, PTSD, and suicide ideation. There are three distinct sleep health programs that will be evaluated; participants will be randomly assigned to one of five groups to receive different combinations of the sleep health programs. To measure results, researchers will use participant surveys for all enrolled participants and wearable sleep-tracking devices for a sub-set of participants. The study team expects that Marines who receive the most comprehensive version of the program will show the greatest improvements in sleep and psychological well-being.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Sleep Leadership — This classroom-style educational training was designed by Adler and colleagues (2021) specifically for Army leaders, based on research showing that perceptions of their leader's sleep-related behaviors can impact unit member's sleep (Gunia et al., 2015). The one-hour training includes a combination of PowerPoint slides, video clips, and handouts with content targeting five leader behaviors denoted using the acronym "SLEEP": Set conditions for adequate sleep through work stress mitigation and environmental conditions; Lead by example; Educate Soldiers about caffeine, alcohol, and substances; Encourage awareness and responsibility among Soldiers; Prioritize sleep and recovery during and after missions.
  • Behavioral: Circadian, Light, and Sleep Skills in Shipboard Military (CLASS-MC) Personnel Program — CLASS-MC is a sleep and circadian health-focused educational program originally designed for shipboard Sailors (Schmied et al., 2022) adapted in the current study for Marines. CLASS-MC includes a 30-minute presentation that is delivered in-person. The curriculum includes information on the purpose and benefits of sleep, basic information about circadian health, and detailed and feasible strategies for how to maximize sleep and circadian health in operational conditions.
  • Behavioral: Insomnia Coach — This intervention is a mobile app developed by researchers at the Department of Veterans Affairs (VA; Kuhn et al., 2022). Insomnia Coach is based on principles of CBT-I, and includes various content modules, such as a daily sleep diary, psychoeducation, and personalized feedback recommendations provided by a feature called "Sleep Coach" (Kuhn et al., 2022).

Primary Outcomes

  • Depression symptoms (Change from baseline to 6-, 12-, and 24-weeks post-baseline)
  • Sleep Quality (Change from baseline to 6-, 12-, and 24-weeks post-baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-03-31
Completion: 2027-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 860 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: San Diego State University
Collaborators: Uniformed Services University of the Health Sciences, Palo Alto Veterans Institute for Research
Principal Investigators:
  • Emily Schmied, PhD (PRINCIPAL_INVESTIGATOR) - eschmied@sdsu.edu
Contact Information
Study Contact:
Emily Schmied, PhD
619-594-6317
eschmied@sdsu.edu
Emily Schmied
619-594-6317
eschmied@sdsu.edu
San Diego State University
Emily Schmied
San Diego State University
Interventions
  • Behavioral: Sleep Leadership — This classroom-style educational training was designed by Adler and colleagues (2021) specifically for Army leaders, based on research showing that perceptions of their leader's sleep-related behaviors can impact unit member's sleep (Gunia et al., 2015). The one-hour training includes a combination of PowerPoint slides, video clips, and handouts with content targeting five leader behaviors denoted using the acronym "SLEEP": Set conditions for adequate sleep through work stress mitigation and environmental conditions; Lead by example; Educate Soldiers about caffeine, alcohol, and substances; Encourage awareness and responsibility among Soldiers; Prioritize sleep and recovery during and after missions.
  • Behavioral: Circadian, Light, and Sleep Skills in Shipboard Military (CLASS-MC) Personnel Program — CLASS-MC is a sleep and circadian health-focused educational program originally designed for shipboard Sailors (Schmied et al., 2022) adapted in the current study for Marines. CLASS-MC includes a 30-minute presentation that is delivered in-person. The curriculum includes information on the purpose and benefits of sleep, basic information about circadian health, and detailed and feasible strategies for how to maximize sleep and circadian health in operational conditions.
  • Behavioral: Insomnia Coach — This intervention is a mobile app developed by researchers at the Department of Veterans Affairs (VA; Kuhn et al., 2022). Insomnia Coach is based on principles of CBT-I, and includes various content modules, such as a daily sleep diary, psychoeducation, and personalized feedback recommendations provided by a feature called "Sleep Coach" (Kuhn et al., 2022).
Study Locations (1 sites)
San Diego State University, San Diego, California 92182 United States
Eligibility Criteria
Inclusion Criteria: * Age 18+ * Able to read and write in English * Currently serving as an active duty member of the U.S. Marine Corp * Currently assigned to duty at the approved study site Exclusion Criteria: * Planned deployment or training operation lasting 30 days or longer and /or planned change of duty station within the study period (i.e., 24 weeks postrecruitment) * Under 18 years of age * Unable to read and write in English
Conditions Bipolar Disorder, Schizophrenia, Depress...
Phase NA
Enrollment 336
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

People with mental disorders face frequent stigmatizing attitudes and behaviors from others . In response to this, they tend to isolate themselves, with the risk of impeding care and the process of recovery and integration into society . Stigmatization can also be assimilated by patients themselves - i.e. self-stigma. Self-stigma is involved in diminished coping skills that lead to social avoidance and difficulties in adhering to care . Reducing self-stigma and its emotional corollary, shame, is thus crucial to attenuate the disability associated with mental illness. Shame is inherent to self-stigma and leads to difficulties in adhering to care as well as greater severity of clinical presentations . Compassion Focused Therapy (CFT) is a third wave cognitive behavioral therapy that targets shame reduction and hostile self-to-self relationship and allows for symptom improvement while increasing self-compassion, a major resilience factor . Although shame is a prominent part of the concept of self-stigma, the efficacy of CFT has never been evaluated in individuals with high levels of self-stigma. In this study, the investigators will evaluate the efficacy and acceptability of a group based CFT program on decreasing self-stigma, compared to treatment as usual (TAU) and a psychoeducation program whose efficacy has been assessed in a previous trial.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Compassion Focused Therapy — CFT is an experiential therapy. As such, in addition to psychoeducation components (e.g.: compassion from an evolutionary and neuroscientific perspective, the tricky brain problem, emotion regulation systems) and explicit learning of emotion regulation skills (in particular, shame), experiential exercises are provided in-sessions (e.g. : chair work, role plays, guided mental imagery, …) and between sessions practices will be provided with video guides, made available for the participants online (e.g. : soothing rhythm breathing, safe place imagery, compassionate self-imagery, …). The overall aim of the CFT program is to help participants shift from a hostile and critical self-to-self relationship to a more compassionate relationship to self.
  • Behavioral: Ending Self Stigma — Psychoeducation sessions cover topics such as the path from public stigma to self-stigma and modifying self-stigmatizing thoughts. Participants will be encouraged to do home practices (e.g. writing about the pros and cons of self-stigmatizing thoughts) between sessions. The overall aim of the ESS program is to help participants address self-stigma with concrete tools to increase their self-esteem and achieve their goals

Primary Outcomes

  • Internalized Stigma of Mental Illness inventory (ISMI) (Day 0)
  • Internalized Stigma of Mental Illness inventory (ISMI) (Month 1)
  • Internalized Stigma of Mental Illness inventory (ISMI) (Month 2)
  • Internalized Stigma of Mental Illness inventory (ISMI) (Month 3)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-04-03
Completion: 2028-03-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 336 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Strasbourg, France
Contact Information
Study Contact:
Luisa Weiner
0033388116312
weiner@unistra.fr
David MISDRAHI, MD
33.5.56.56.34.49
david.misdrahi@u-bordeaux.fr
Pôle de Psychiatrie Adulte, Hôpital Charles Perrens
David MISDRAHI, MD
Pôle de Psychiatrie Adulte, Hôpital Charles Perrens
Interventions
  • Behavioral: Compassion Focused Therapy — CFT is an experiential therapy. As such, in addition to psychoeducation components (e.g.: compassion from an evolutionary and neuroscientific perspective, the tricky brain problem, emotion regulation systems) and explicit learning of emotion regulation skills (in particular, shame), experiential exercises are provided in-sessions (e.g. : chair work, role plays, guided mental imagery, …) and between sessions practices will be provided with video guides, made available for the participants online (e.g. : soothing rhythm breathing, safe place imagery, compassionate self-imagery, …). The overall aim of the CFT program is to help participants shift from a hostile and critical self-to-self relationship to a more compassionate relationship to self.
  • Behavioral: Ending Self Stigma — Psychoeducation sessions cover topics such as the path from public stigma to self-stigma and modifying self-stigmatizing thoughts. Participants will be encouraged to do home practices (e.g. writing about the pros and cons of self-stigmatizing thoughts) between sessions. The overall aim of the ESS program is to help participants address self-stigma with concrete tools to increase their self-esteem and achieve their goals
Study Locations (7 sites)
Pôle de Psychiatrie Adulte, Hôpital Charles Perrens, Bordeaux, 33076 France
Ch Le Vinatier, Bron, 69678 France
CHU de Clermont-Ferrand, Hôpital Gabriel Montpied, Service de Psychiatrie B, Clermont-Ferrand, 63003 France
Pôle Hospitalo-Universitaire de Psychiatrie d'adultes et d'addictologie du Grand Nancy, Centre Psychothérapique de Nancy, Laxou, 54520 France
CHU de Montpellier, Psychiatrie d'adultes, Hôpital la Colombière, Montpellier, 34295 France
Etablissement Public de Santé Mentale (EPSM) de la Marne, Site Pierre-Briquet, Unité de réhabilitation psychosociale, Reims, 51100 France
Service de Psychiatrie, Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, 67091 France
Eligibility Criteria
Inclusion Criteria: 1. Patient ≥18 years of age 2. Patient informed of the results of the preliminary medical examination 3. Patient affiliated to a social health insurance plan (beneficiary or beneficiary's family) 4. Patient with one or several diagnoses of chronic psychiatric disorder (schizophrenia, schizoaffective disorder, bipolar disorder, recurrent major depression, borderline personality disorder) or a neurodevelopmental disorder (autism spectrum disorder) treated as an outpatient or in a day hospital 5. CGI-Severity score\<6 assessed by the psychiatrist (Berk et al., 2008) ISMI score indicating moderate to high self-stigma (\>2.5; Lysaker et al., 2007) Exclusion criteria: 6. Patient in an exclusion period determined by a previous or ongoing study 7. Patient participating in an interventional study involving psychotherapy or an experimental drug 8. Patient in acute episode of their disorder according to the CGI Severity score 9. Patient in a medical emergency or immediate life-threatening situation 10. Patients with an intellectual disability (IQ\<70) estimated via the fNART (Mackinnon \& Mulligan, 2005) 12\. Legal issues: care under constraint or patient deprived of freedom because of a judicial measure 13. Patient who does not speak and read French sufficiently
Conditions Perinatal Depression, Perinatal Anxiety
Phase NA
Enrollment 3000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

This study is part of the e-Perinatal project and is embedded within the main cluster randomized trial. The primary aim is to evaluate the feasibility, acceptability, and preliminary effectiveness of an early diagnosis detection and referral strategy to specialized mental health services within routine maternal care. The secondary aim is to validate and implement an Artificial Intelligence-based algorithm for the early screening of mental health disorders in routine services.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: The e-Perinatal intervention is a personalized mobile health (mHealth) program — The e-Perinatal intervention is a personalized mobile health (mHealth) program that includes: 1) Digital micro-interventions focused on psychological, physical activity, and healthy lifestyle domains; 2) a personalized recommendation engine; 3) a social support section; 4) mental health monitoring; 5) an 'SOS' button for assistance; and 6) an appointment reminder tool. The intervention is delivered through a mobile application and is integrated into routine maternal care. Participants will use the app from recruitment (pregnancy) until 12 months of postpartum.
  • Other: Standard routine maternal care — Participants will receive standard maternal care as provided by the public healthcare system, including routine antenatal and postnatal visits and access to maternal education programs.

Primary Outcomes

  • Feasibility of referral strategy (Baseline, 12 months postpartum)
  • Acceptability of the referral (through study completion, an average of 18 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-15
Completion: 2028-03-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 3000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Seville
Collaborators: Andalusian Health Service, Junta de Andalucia
Principal Investigators:
  • Emma Motrico, PhD (PRINCIPAL_INVESTIGATOR) - University of Seville
Contact Information
Study Contact:
Emma Motrico, PhD
0034636995778
eperinatal@us.es
Ana Belén Naranjo Saucedo,, MSc
+34 676426430
ana.naranjo@juntadeandalucia.es
Primary Health Care Center Mairena del Aljarafe - Ciudad Expo
Interventions
  • Behavioral: The e-Perinatal intervention is a personalized mobile health (mHealth) program — The e-Perinatal intervention is a personalized mobile health (mHealth) program that includes: 1) Digital micro-interventions focused on psychological, physical activity, and healthy lifestyle domains; 2) a personalized recommendation engine; 3) a social support section; 4) mental health monitoring; 5) an 'SOS' button for assistance; and 6) an appointment reminder tool. The intervention is delivered through a mobile application and is integrated into routine maternal care. Participants will use the app from recruitment (pregnancy) until 12 months of postpartum.
  • Other: Standard routine maternal care — Participants will receive standard maternal care as provided by the public healthcare system, including routine antenatal and postnatal visits and access to maternal education programs.
Study Locations (1 sites)
Primary Health Care Center Mairena del Aljarafe - Ciudad Expo, Mairena del Aljarafe, Sevilla 41927 Spain
Eligibility Criteria
Inclusion Criteria: * Pregnant and postpartum women enrolled in the main e-Perinatal trial, indicating the presence of a depressive or anxiety disorder with CIDI. * Access to smartphone and internet * Able to write and read in Spanish Exclusion Criteria: * None beyond those defined in the main trial

Dapagliflozin in Depression

NCT07239011
Recruiting
Conditions Depression
Phase PHASE1, PHASE2
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

Major depressive disorder (MDD) is currently one of the leading causes of disability and suicidal death worldwide, and despite extensive research and massive improvements in mental health, the nature of MDD remains ambiguous. Moreover, about two-thirds of MDD patients fail to optimally respond to currently available standard therapies, and many of them suffer from treatment-resistant depression

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Fluoxetine — Fluoxetine is an antidepressant medication of the selective serotonin reuptake inhibitor class used for the treatment of major depressive disorder, anxiety, obsessive-compulsive disorder, panic disorder, premenstrual dysphoric disorder, and bulimia nervosa.
  • Drug: Dapagliflozin — Dapagliflozin is a medication used to treat type 2 diabetes. It is also used to treat adults with heart failure and chronic kidney disease. It reversibly inhibits sodium-glucose co-transporter 2 (SGLT-2) in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose excretion.

Primary Outcomes

  • The primary outcome measure was the 17-item HDRS. (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-11-01
Completion: 2026-12-20
Eligibility
Age: 18 Years – 60 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tanta University
Contact Information
Study Contact:
Mostafa Bahaa, PhD
0201025538337
mbahaa@horus.edu.eg
Mostafa Bahaa
Interventions
  • Drug: Fluoxetine — Fluoxetine is an antidepressant medication of the selective serotonin reuptake inhibitor class used for the treatment of major depressive disorder, anxiety, obsessive-compulsive disorder, panic disorder, premenstrual dysphoric disorder, and bulimia nervosa.
  • Drug: Dapagliflozin — Dapagliflozin is a medication used to treat type 2 diabetes. It is also used to treat adults with heart failure and chronic kidney disease. It reversibly inhibits sodium-glucose co-transporter 2 (SGLT-2) in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose excretion.
Study Locations (1 sites)
Mostafa Bahaa, Damietta, New Damietta 34518 Egypt
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years Both male and female will be included Negative pregnancy test and effective contraception. Depressed patients for at least 2 months with Hamilton rating score more than 18. Exclusion Criteria: Patients with bipolar I or bipolar II disorder, personality disorders, and eating disorders. Patients with substance dependence or abuse Patients with history of seizures or receiving electroconvulsive therapy (ECT) Patients with inflammatory disorders Patients with allergy or contraindications to the used medications Patients with finally pregnant or lactating females Diabetic patients Sever kidney disorders
Conditions Major Depressive Disorder (MDD)
Phase NA
Enrollment 24
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to test whether an accelerated deep Transcranial Magnetic Stimulation (dTMS) protocol can reduce depressive symptoms in older adults (ages 60-85) with Major Depressive Disorder (MDD) who have not tolerated or responded to antidepressant medications. The study will evaluate whether accelerated dTMS administered over 5 consecutive days is safe and well-tolerated in this population, and whether it produces greater reductions in depressive symptoms compared to placebo stimulation.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: Active Brainsway H7-Coil Deep TMS System — Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered 6-8 times a day for 5 consecutive days.
  • Device: Sham Brainsway H1-Coil Deep TMS System — In addition to the active H7-coil, a sham coil is included in the H1-coil helmet. The sham treatment will be administered 6-8 times a day for 5 consecutive days.

Primary Outcomes

  • Percentage of scheduled treatment sessions that are attended by study participants (6 weeks)
  • Participant-reported comfort and feasibility based on the frequency and type of adverse events as measured using the Adverse Events Questionnaire (AEQ) (6 weeks)
  • The number of participants who have prematurely withdraw and reasons for withdrawal (6 weeks)
  • The change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) scores following the final treatment on day 5 (i.e., after 5 days of H7-coil a-iTBS) in the treatment group compared to the sham group. (1 week)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-21
Completion: 2027-02-15
Eligibility
Age: 60 Years – 85 Years
Sex: ALL
Volunteers: false
Enrollment: 24 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Rotman Research Institute at Baycrest
Principal Investigators:
  • Linda Mah, MD (PRINCIPAL_INVESTIGATOR) - Baycrest Rotman Research Institute
Contact Information
Study Contact:
Amanda Chao, MPH
416-785-2500
preventad@research.baycrest.org
Linda Mah, MD
416-785-2500
preventad@research.baycrest.org
Linda Mah, MD
416-785-2500
preventad@research.baycrest.org
Rotman Research Institute at Baycrest
Interventions
  • Device: Active Brainsway H7-Coil Deep TMS System — Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered 6-8 times a day for 5 consecutive days.
  • Device: Sham Brainsway H1-Coil Deep TMS System — In addition to the active H7-coil, a sham coil is included in the H1-coil helmet. The sham treatment will be administered 6-8 times a day for 5 consecutive days.
Study Locations (1 sites)
Rotman Research Institute at Baycrest, Toronto, Ontario M6A 2E1 Canada
Eligibility Criteria
Inclusion Criteria: * are between 60- 85 years old (on the day of randomization) * have been diagnosed with DSM5 Major Depressive Disorder, with the current episode longer than 4 weeks but less than 5 years * did not respond to/did not tolerate, or failed to achieve remission with at least one antidepressant trial of 8 week minimum duration * are willing to provide informed consent * are able to follow the treatment schedule * are stable on medications for 2 months and are not expected to change medication during the entire study period (if they are taking medications) * have a satisfactory safety screening questionnaire for TMS Exclusion Criteria: * have a metal plate in your head (such as an ear implant, implanted brain stimulators, aneurysm clips). Dental devices and implants that are non-magnetic are safe * have known increased pressure or a history of increased pressure in their brain, which may increase their risk for having seizures * have a cardiac pacemaker * have an implanted medication pump * have a central venous line * have a history of any psychotic disorder, bipolar disorder, eating disorder, obsessive compulsive disorder, post-traumatic stress disorder, or dementia * have a history of substance abuse in the last 6 months * have a history of stroke or other brain lesions * have a personal history of epilepsy * have a family history of epilepsy * are a pregnant or breast-feeding woman * have a history of abnormal MRI of the brain * have untreated hypo- or hyper-thyroidism * have unstable medical condition(s) * have any other known contraindications to TMS * are on unstable doses of any psychotropic medication such as - antidepressants, antipsychotic, mood stabilizers or memory enhancing medications * require daily doses of benzodiazepines or hypnotics within two weeks of randomization
Conditions Smoking Cessation, Depression, Anxiety, ...
Phase NA
Enrollment 100
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

Smoking remains the leading preventable cause of death in the United States, and there are persistent and significant disparities in tobacco use among transgender and gender diverse (TGD) individuals. Stigma, discrimination, gender dysphoria, and other gender minority stressors likely contribute to these disparities, and the increased burden of gender minority stress may also be driving higher prevalence rates of anxiety and depression, both of which are more common among TGD individuals and among those who smoke relative to comparison samples. This study will (1) explore the ways in which gender minority stressors and associated anxiety and depression compromise smoking cessation among TGD individuals, identifying elements in an existing smoking cessation intervention that need to be adjusted to meet their unique needs; (2) adapt an existing smoking cessation intervention for TGD individuals; and (3) evaluate the feasibility and acceptability of the adapted intervention in a pilot randomized controlled trial.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: PRIDE QUIT — This is an adapted behavioral intervention based on the integrated treatment for smoking cessation, anxiety, and depressed mood, known as QUIT, for persons with HIV. Through our treatment adaption process of QUIT (guided by Aim 1 and 2 data), PRIDE QUIT will be a Cognitive-Behavioral therapy-based intervention tailored for transgender and gender diverse (TGD) individuals, aimed at to helping participants quit smoking and address gender minority stressors, anxiety, depression, and improve distress tolerance. There will be three major assessments: baseline (T1), at the end of the intervention (T2), and a three-month follow-up visit (T3). This intervention group will receive a pre-randomization general educational session (session 0) followed by 5 weekly sessions and a booster sessions 4 weeks after T2, with the quit day set between sessions 3 and 4.
  • Behavioral: Enhanced Treatment As Usual (ETAU) — Brief counseling, American Cancer Society cessation resources (palm card with information on how to access the American Cancer Society website) after pre-randomization educational session (session 0,) the option of nicotine replacement therapy, and referral to the Quit Line.

Primary Outcomes

  • Acceptability (Through the end of treatment intervention, approximately 6 weeks)
  • Feasibility of the Intervention (Through participants' enrollment, approximately 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-01
Completion: 2027-08-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Conall M O'Cleirigh, PhD (PRINCIPAL_INVESTIGATOR) - Massachusetts General Hospital, Behavioral Medicine Program
  • Amelia Stanton, PhD (PRINCIPAL_INVESTIGATOR) - Boston University
Contact Information
Study Contact:
Conall M O'Cleirigh, PhD
617-643-0385
cocleirigh@mgh.harvard.edu
Amelia Stanton, PhD
617-724-6300
stantona@bu.edu
Elizabeth Loynd
617-927-6216
eloynd@fenwayhealth.org
Fenway Health
Interventions
  • Behavioral: PRIDE QUIT — This is an adapted behavioral intervention based on the integrated treatment for smoking cessation, anxiety, and depressed mood, known as QUIT, for persons with HIV. Through our treatment adaption process of QUIT (guided by Aim 1 and 2 data), PRIDE QUIT will be a Cognitive-Behavioral therapy-based intervention tailored for transgender and gender diverse (TGD) individuals, aimed at to helping participants quit smoking and address gender minority stressors, anxiety, depression, and improve distress tolerance. There will be three major assessments: baseline (T1), at the end of the intervention (T2), and a three-month follow-up visit (T3). This intervention group will receive a pre-randomization general educational session (session 0) followed by 5 weekly sessions and a booster sessions 4 weeks after T2, with the quit day set between sessions 3 and 4.
  • Behavioral: Enhanced Treatment As Usual (ETAU) — Brief counseling, American Cancer Society cessation resources (palm card with information on how to access the American Cancer Society website) after pre-randomization educational session (session 0,) the option of nicotine replacement therapy, and referral to the Quit Line.
Study Locations (3 sites)
Massachusetts General Hopsital, Boston, Massachusetts 02114 United States
Boston University - Charles River Campus, Boston, Massachusetts 02215 United States
Fenway Health, Boston, Massachusetts 02215 United States
Eligibility Criteria
Inclusion Criteria: 1. aged 18+ 2. self-reported difference between sex assigned at birth and gender identity 3. current use of combustible cigarettes (defined as self-reported 5 combustible cigarettes per day in any week in the past month and a carbon monoxide \[CO\] expired-air reading of ≥8ppm) OR current use of nicotine-containing e-cigarettes (defined by saliva cotinine level of ≥30ng/mL) with use of combustible cigarettes (5 cigarettes per day in any week in the past month) 4. desire to stop using tobacco products (defined by ≥5 on the Motivational Aspects of Smoking Cessation Questionnaire) 5. English-speaking. Exclusion Criteria: 1. unable to provide informed consent 2. current interfering untreated or unstable major health condition (e.g., bipolar, current psychosis) 3. current use of psychotherapy for smoking cessation 4. participation in Aim 1a procedures.
Conditions Depressive Symptoms
Phase NA
Enrollment 207
Locations 13 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

Preliminary findings from a previous study conducted by the investigators suggest that a task-shared approach with modified mindfulness-based cognitive therapy (MBCT) supported by social workers is beneficial in managing depressive symptoms and improving mindful non-reactivity among older adults. However, the possibility for social workers to lead a mindfulness-based intervention (MBI) independently to improve its scalability and service accessibility remains unclear. The project aims to: 1. Evaluate the effectiveness of social worker-led MBI in improving depression in older adults with mild to moderate depressive symptoms as compared to care as usual; 2. Examine the effectiveness of incorporating peer supporters in social worker-led MBI compared to those without peer supporters; 3. To identify potential mechanisms of change in MBI for depressive symptoms.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Mindfulness-based intervention (MBI) (enhanced with peer supporters) — Mindfulness-based intervention combines mindfulness meditation with cognitive behavioural therapy (CBT) elements to reduce or prevent recurrent major depressive disorders. On-site support and regular follow-up by peer supporters.
  • Behavioral: Experimental: social worker-led MBI (without peer supporters) — Mindfulness-based intervention combines mindfulness meditation with cognitive behavioural therapy (CBT) elements to reduce or prevent recurrent major depressive disorders.

Primary Outcomes

  • Change from baseline depression at Week 6 and Week 18 (Baseline and Week 6, Week 18)
  • Change from baseline anxiety at Week 6 and Week 18 (Baseline and Week 6, Week 18)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-07-23
Completion: 2026-03-16
Eligibility
Age: 60 Years and older
Sex: ALL
Volunteers: false
Enrollment: 207 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Hong Kong
Collaborators: The Hong Kong Jockey Club Charities Trust, Christian Family Service Centre, The Mental Health Association of Hong Kong, The Salvation Army, Hong Kong and Macau Command, Haven of Hope Hospital, Hong Kong Sheng Kung Hui, Tung Wah Group of Hospitals, Aberdeen Kai-fong Welfare Association, Hong Kong Society for the Aged, Neighbourhood Advice-Action Council
Principal Investigators:
  • Terry YS Lum, PhD (PRINCIPAL_INVESTIGATOR) - Department of Social Work and Social Administration, The University of Hong Kong
Contact Information
Study Contact:
Dara KY Leung, PhD
3917-0081
daralky@hku.hk
Zuna LY Ng
zunang@hku.hk
Wing Sze Chow
+852-2563-0187
winnie.chow@sage.org.hk
Hong Kong Society for the Aged
Interventions
  • Behavioral: Mindfulness-based intervention (MBI) (enhanced with peer supporters) — Mindfulness-based intervention combines mindfulness meditation with cognitive behavioural therapy (CBT) elements to reduce or prevent recurrent major depressive disorders. On-site support and regular follow-up by peer supporters.
  • Behavioral: Experimental: social worker-led MBI (without peer supporters) — Mindfulness-based intervention combines mindfulness meditation with cognitive behavioural therapy (CBT) elements to reduce or prevent recurrent major depressive disorders.
Study Locations (13 sites)
Hong Kong Society for the Aged, Eastern District, Hong Kong
HKSKH Lok Man Alice Kwok Integrated Service Centre, Kowloon City, Hong Kong
SKH Holy Carpenter Church, Kowloon City, Hong Kong
The Mental Health Association of Hong Kong, Kwun Tong, Hong Kong
Haven of Hope District Elderly Community Service, Sai Kung, Hong Kong
Wellness Zone - Integrated Community Centre for Mental Wellness, Sai Kung, Hong Kong
HKSKH Western District Elderly Community Centre, Sai Wan, Hong Kong
TWGHs Lok Hong Integrated Community Centre for Mental Wellness, Sai Wan, Hong Kong
Wilson T.S. Wang District Elderly Community Centre, Shatin, Hong Kong
Aberdeen Kai-fong Welfare Association, Southern District, Hong Kong
Eligibility Criteria
Inclusion Criteria: * 60 years or older * have depressive symptoms of mild level or above, as indicated by scoring 5-14 on PHQ-9 * can give informed consent to participate Exclusion Criteria: * known history of autism, intellectual disability, schizophrenia-spectrum disorder, bipolar disorder, Parkinson's disease, or dementia * current abuse of drugs or alcohol * difficulty in communication * imminent suicidal risk * timing or training is unsuitable for the participant
Conditions Emotional Regulation, Depression, Anxiet...
Phase NA
Enrollment 390
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

The proposed study is designed to first test whether teaching people personalized or standardized emotion regulation skills leads to greater decreases in daily negative emotion intensity. Second, using data from an initial sample, the investigators will prospectively assign an independent sample of participants to receive their predicted optimal or non-optimal skills to determine if it is feasible and efficacious to match participants to the most appropriate training condition. Results of these studies may identify the mechanisms by which emotion regulation interventions impact emotional functioning and allow for the development of personalized, evidence-based, and scalable emotion regulation interventions.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Checking the Facts — Checking the Facts is a form of cognitive reappraisal in which participants identify negatively-valenced automatic thoughts and both generate and consider evidence that challenges the validity of those thoughts.
  • Behavioral: Opposite to Emotion Action — Opposite to Emotion Action teaches participants to identify their momentary emotion(s), identify the associated behavioral urge(s), and implement a behavior inconsistent with that urge (e.g., approaching a feared stimulus instead of avoiding it).
  • Behavioral: Mindfulness of Current Emotions — Mindfulness of Current Emotions teaches participants to nonjudgmentally observe the experience of their emotions, including physiological and cognitive responses to those emotions.

Primary Outcomes

  • Changes in Positive and Negative Affect Schedule-Short Form (7 times per day for 42 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-29
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 390 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Matthew Southward, PhD
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Matthew W Southward, Ph.D. (PRINCIPAL_INVESTIGATOR) - Ohio State University
Contact Information
Study Contact:
Matthew W Southward, Ph.D.
614-247-0331
copingskillsstudy@gmail.com
Matthew W Southward, Ph.D.
614-247-0331
copingskillsstudy@gmail.com
Ohio State University
Interventions
  • Behavioral: Checking the Facts — Checking the Facts is a form of cognitive reappraisal in which participants identify negatively-valenced automatic thoughts and both generate and consider evidence that challenges the validity of those thoughts.
  • Behavioral: Opposite to Emotion Action — Opposite to Emotion Action teaches participants to identify their momentary emotion(s), identify the associated behavioral urge(s), and implement a behavior inconsistent with that urge (e.g., approaching a feared stimulus instead of avoiding it).
  • Behavioral: Mindfulness of Current Emotions — Mindfulness of Current Emotions teaches participants to nonjudgmentally observe the experience of their emotions, including physiological and cognitive responses to those emotions.
Study Locations (1 sites)
Ohio State University, Columbus, Ohio 43210 United States
Eligibility Criteria
Inclusion Criteria: * Elevated emotion dysregulation Exclusion Criteria: * Lack of proficiency in English * No access to smartphone * Conditions requiring greater than outpatient care
Conditions Young Adults, Hypertension, Post-Exercis...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to learn how exercise timing affects blood pressure in adults with elevated or high blood pressure. Exercise can influence the body's natural 24-hour rhythms, including blood pressure patterns. A single exercise session can lower blood pressure for up to 24 hours, but it is not fully understood how the time-of-day for exercise affects this response. The main question this study aims to answer is: • When the same participant exercises at different times of day (morning, afternoon, or evening), how does this affect the participant's blood pressure over the next 24 hours? Participants will: * Undergo an in-lab assessment of individual biological rhythm that will indicate the clock-time for an individual's biological night * Complete 3 supervised treadmill exercise sessions * 1 in the biological morning (biological night + 10 hours) * 1 in the biological afternoon (biological night + 15 hours) * 1 in the biological evening (biological night + 20 hours) * Complete a 24-hour blood pressure assessment before and after each exercise session

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Exercise — A single standardized, in-lab, 30-minute monitored treadmill exercise session

Primary Outcomes

  • Average daytime systolic blood pressure (24-hours)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-22
Completion: 2026-09
Eligibility
Age: 18 Years – 39 Years
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Freda Patterson
Contact Information
Study Contact:
Freda Patterson, PhD
302-831-6588
fredap@udel.edu
Thomas Keiser
302-831-6588
tkeiser@udel.edu
Thomas Keiser
302-831-6588
tkeiser@udel.edu
University of Delaware
Interventions
  • Behavioral: Exercise — A single standardized, in-lab, 30-minute monitored treadmill exercise session
Study Locations (1 sites)
University of Delaware, Newark, Delaware 19713 United States
Eligibility Criteria
Inclusion Criteria: * 18-39 Years old * Resting blood pressure greater than or equal to 120/80 mmHg or less than 140/90 mmHg Exclusion Criteria: * Diagnosis or history of chronic or autoimmune disease (i.e., cardiovascular, metabolic, renal, endocrine, cancer) * Diagnosis or history of sleep disorder (i.e., obstructive sleep apnea, insomnia, restless leg syndrome) * Alcohol or drug dependence * Elevated risk for sleep disorders * Elevated risk for clinical depression * Normotensive (blood pressure less than 120/80 mmHg) or stage 2+ hypertension (blood pressure greater than or equal to 140/90 mmHg) * Body mass index less than 18.5 or greater than 35 kg/m2 * Self-reported use of sleep medications/supplements (e.g., melatonin) * Self-reported use of medications influencing vascular physiology (e.g., antihypertensive medications, weight loss medications) * Highly physically active (greater than or equal to 300 minutes moderate-to-vigorous physical activity per week) * Currently pregnant or breastfeeding * Current tobacco use (greater than or equal to 1 cigarette in the past month) * Nighttime or rotating shift work within the last 3 months * Contraindications to aerobic exercise